Returned drug money should not fund waiting list drive

Stephen Whitehead

The billions of pounds due to be clawed back from pharma firms under a new NHS pricing deal should not be diverted to help hospitals cut waiting lists, the head of the Association of British Pharmaceutical Industry has urged.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here